Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Identifying and applying molecular subgrouping in colorectal cancer

Share :

WIN Symposium 2013

10 - 12 Jul 2013
Published: 18 Jul 2013
Views: 5370
Rating:
Save
Dr Sabine Tejpar - University of Leuven, Leuven, Belgium

Dr Sabine Tejpar talks to ecancer that 2013 WIN Symposium about understanding the patterns for treating colorectal cancer and drug development, including novel agents.

 

Filmed in Partnership with the WIN Consortium

Related Videos

ESMO 2023: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Nov 2023
Potential benefit to response rates from trastuzumab added to perioperative...
Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )
6 Jul 2023
Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC
Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh...
Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC ( Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia )
27 Apr 2023
Latest treatments in oesophageal cancer
Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA
Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )
5 Apr 2023
Trifluridine/tipiracil plus bevacizumab improves OS in mCRC
Dr Josep Tabernero - Vall d’Hebron University Hospital, Barcelona, Spain
Trifluridine/tipiracil plus bevacizumab improves OS in mCRC ( Dr Josep Tabernero - Vall d’Hebron University Hospital, Barcelona, Spain )
7 Feb 2023
Genomic testing in biliary tract cancers
Dr Chiara Braconi - University of Glasgow, Glasgow, UK
Genomic testing in biliary tract cancers ( Dr Chiara Braconi - University of Glasgow, Glasgow, UK )
24 Oct 2022
ERMES study suggests a strategy of de-escalation with only cetuximab in first...
Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy
ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC ( Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy )
14 Sep 2022
An overview of treatment advances in gastric cancer
Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA
An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )
18 Aug 2022
MOUNTAINEER: Tucatinib in combination with trastuzumab for HER2-positive mCRC
Dr Jonathan Strickler - Duke Cancer Institute, Durham, USA
MOUNTAINEER: Tucatinib in combination with trastuzumab for HER2-positive mCRC ( Dr Jonathan Strickler - Duke Cancer Institute, Durham, USA )
8 Aug 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation